ANI Pharmaceuticals (NASDAQ:ANIP) Given New $62.00 Price Target at Truist Financial

ANI Pharmaceuticals (NASDAQ:ANIP) had its price objective raised by Truist Financial from $60.00 to $62.00 in a research report released on Tuesday morning, Benzinga reports. The firm currently has a hold rating on the specialty pharmaceutical company’s stock.

Other research analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Finally, Raymond James upped their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $77.33.

ANI Pharmaceuticals Trading Up 1.3 %

Shares of ANI Pharmaceuticals stock opened at $60.08 on Tuesday. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of 37.55 and a beta of 0.71. The business has a fifty day simple moving average of $59.51 and a 200-day simple moving average of $62.21. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. During the same period in the prior year, the business posted $1.06 earnings per share. ANI Pharmaceuticals’s revenue was up 18.5% compared to the same quarter last year. On average, equities analysts forecast that ANI Pharmaceuticals will post 3.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ANIP. Allspring Global Investments Holdings LLC increased its holdings in shares of ANI Pharmaceuticals by 287.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after acquiring an additional 15,790 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of ANI Pharmaceuticals by 8.2% during the 1st quarter. Principal Financial Group Inc. now owns 87,699 shares of the specialty pharmaceutical company’s stock valued at $6,063,000 after acquiring an additional 6,626 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of ANI Pharmaceuticals by 106.9% during the 1st quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock valued at $1,434,000 after acquiring an additional 10,716 shares during the last quarter. Wakefield Asset Management LLLP acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at about $979,000. Finally, Hussman Strategic Advisors Inc. acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at about $2,178,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.